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Introduction {#sec1}
============

Vascularization is an essential physiological process that occurs during embryonic and fetal development and in disease ([@bib4]). It is well documented that endothelial cells arise from precursors ([@bib15], [@bib33]) of the splanchnopleural or paraxial mesoderm ([@bib18]). Among mesodermal cells, hemangioblasts that differentiate into both hematopoietic and endothelial cells ([@bib6], [@bib10]) have received much attention, but they are spatially restricted to the periphery of the endoderm as well as the aorta-gonad-mesonephros region at later stages of development ([@bib9]). Therefore, endothelial cells would be expected to also derive from mesodermal progenitors devoid of hematopoietic potential.

Recently, [@bib33] proposed the existence of a mesoderm-derived bipotent progenitor cell, the so-called mesenchymoangioblast, which could be derived and characterized from embryonic stem cells. Although hemangioblast and hemogenic endothelium have been broadly characterized during development (reviewed in [@bib6]), precursors for mesenchymoangioblasts with both endothelial and mesenchymal potential have seldom been explored *in vivo*. In this regard, [@bib2] identified vessel-associated progenitors, "mesoangioblasts," with potential to form both vessel and associated cells in murine models. Mesoangioblasts isolated from dorsal aorta at embryonic day 9.5 demonstrated extensive self-renewal capacity with the potential to form most mesodermal lineages on transplantation ([@bib15]). Moreover, given the similarity of their surface marker profile with mesenchymal stem cells (MSCs), mesoangioblasts were proposed as the ancestors of postnatal MSCs ([@bib13], [@bib15], [@bib24]). Murine experiments reported expression of Flk1 (vascular endothelial growth factor receptor 2) ([@bib7]), CD34, or c-Kit ([@bib15]) in mesoangioblasts. The existence of mesoangioblasts in postnatal life has also been suggested through isolation from muscle pericytes ([@bib3]). Others have reported mesodermal precursors with endothelial capacity in bone marrow ([@bib26], [@bib27]). Despite these various indications in essentially murine studies, the existence of a bipotential population with capacity to give rise to mesenchymal and endothelial progeny in human tissues remains questioned.

The recent description of a functional hierarchy in the endothelium based on colony-formation capacity and proliferative potential has allowed to define progenitors, namely highly proliferative endothelial colony-forming cells (ECFCs) as opposed to low proliferative potential ECFCs or endothelial clusters ([@bib11]). Our group recently demonstrated *in vivo* the heterogeneity and hierarchy of the endothelial compartment in murine vasculature, allowing a functional definition of endothelial progenitors ([@bib20]). We have also demonstrated that human ECFCs as well as human MSCs of fetal origin can be isolated from the term placenta ([@bib19], [@bib21]). Here, we hypothesized that vascularization of the human placenta from mesodermal precursors gives a unique opportunity to prospectively characterize the human mesoangioblast phenotype. Our findings support the existence *in vivo* of meso-endothelial bipotent progenitors capable of giving rise to both endothelial and mesenchymal progeny. Characterization of this progenitor distinguishes it from both mesenchymal (MSCs) and endothelial progenitors (ECFCs) at the functional and molecular level.

Results {#sec2}
=======

Placental EPCs Are Enriched in the CD45^−^CD34^+^ Population {#sec2.1}
------------------------------------------------------------

To evaluate progenitors that would give rise to endothelial cells *in vivo* (called herein EPCs, i.e., endothelial progenitor cells) and able to form highly proliferative colonies in culture (HPP-ECFCs), we adopted a systematic and prospective isolation and culturing strategy. When unsorted term placental cells were cultured in EGM2, this resulted in both mesenchymal ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and endothelial cells ([Figure S1](#mmc1){ref-type="supplementary-material"}B) before passaging. Only 0.011% ± 0.001% of placental cells could form proliferative colonies, and from this only 0.00066% ± 0.0001% were HPP-ECFCs ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Flow cytometry also confirmed that 12.4% ± 3.9% of unsorted placental cells expressed CD31 at primary culture ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Upon passaging and persistent culture, endothelial cells were rapidly outgrown by mesenchymal cells (probably of maternal origin \[[@bib21]\]) with a fibroblastic morphology, expressing MSC surface markers (data not shown).

To enrich for EPCs or bipotential cells with endothelial potential, we next characterized term placental cells according to well-established endothelial (CD31 and CD34) and hematopoietic (CD45) surface markers ([Figures 1](#fig1){ref-type="fig"}A and 1B). Unsorted placental cells consisted mostly of hematopoietic (CD45^+^) cells and comprised a small CD34^+^ fraction.Figure 1Placental Endothelial Progenitor Cells Are Enriched in the CD45^−^CD34^+^ Population(A) To enrich the endothelial colony-forming cell (ECFC) population, we enriched placental cells for CD45^−^CD34^+^ cells.(B) Number of HPP-ECFCs forming cobblestone-like endothelial colonies in this population was superior to the CD45^−^ and the CD45^−^CD34^−^ populations (data presented as mean ± SD).(C) Flow cytometry on placental unsorted cells showing frequency of CD34^+^ or CD34^+^CD45^−^ cells. To further purify EPC we devised a sorting strategy.(D and E) Four different populations were observed based on CD31 levels in CD45^−^CD34^+^ population. Fluorescence minus one analysis (D) demonstrated that (E) one population is CD31 negative, while the three other populations express low, intermediate, and high levels of CD31.(F) Percentage of each population (data presented as mean ± SD).(G--K) CD31Neg cells resulted in pure mesenchymal stem cell (MSC) colonies. Pure endothelial cells were derived from CD31Int and CD31Hi populations; upon culture, CD31Int and CD31Hi cells never formed mesenchymal colonies. EPCs were to be almost exclusively in the CD31Int population. For CD31Low population the number of bipotential colonies is presented (data presented as median with interquartile range). Scale bar, 100 μm.^∗^p \< 0.05 and ^∗∗∗^p \< 0.005.

Upon digestion and single-cell suspension, we used magnetic activated cell sorting (MACS) sorting to isolate and test the colony-forming capacity of different cell fractions ([Figure 1](#fig1){ref-type="fig"}A). Sorting CD45^−^CD34^+^ cells enriched for endothelial potential as the number of HPP-ECFCs in this population was superior to those in the CD45^−^ and the CD45^−^CD34^−^ populations ([Figure 1](#fig1){ref-type="fig"}B). CD34^+^ cells represented a small population of unsorted placental cells (7.9% ± 3.6%), and CD45^−^CD34^+^ represented a fraction of that (3.0% ± 1.2%) ([Figure 1](#fig1){ref-type="fig"}C, n = 10 placentas). However, not all the cells in CD45^−^CD34^+^ showed an endothelial phenotype. In some cultures a significant mesenchymal population still overtook endothelial cells, suggesting that a mesenchymal progenitor could be found in the CD45^−^CD34^+^ population.

Fetal EPCs and MSCs Purified Based on CD31 Expression Levels among CD45^−^CD34^+^ Placental Cells {#sec2.2}
-------------------------------------------------------------------------------------------------

To further purify endothelial from mesenchymal cells in CD45^−^CD34^+^ cells, we made use of the endothelial cell surface antigen CD31 (*PECAM-1*).

Based on CD31 levels, the CD45^−^CD34^+^ cells could be divided into four populations ([Figures 1](#fig1){ref-type="fig"}D and 1E). Fluorescence minus one (FMO) analysis clearly showed that one population was CD31 negative (CD31Neg) and included 24.8% ± 10.4% of CD45^−^CD34^+^, while the three other populations expressed low (CD31Lo), intermediate (CD31Int), and high (CD31Hi) levels of CD31, and included 20.7% ± 3.9%, 25.7% ± 5.6%, and 28.8% ± 8.2% of CD45^−^CD34^+^ cells, respectively ([Figures 1](#fig1){ref-type="fig"}D--1F). We employed a cell-sorting strategy directly from the digested term placenta and cultured these four populations individually in EGM2 to explore their potency ([Figure 1](#fig1){ref-type="fig"}G). Extreme care was taken to reduce the gating width to avoid any overlap in CD31 levels. All fractions expressed CD34 at a high level and were CD45 negative as verified by isotype control, FMO analysis, and RT-PCR (data not shown). Fetal origin of all cells in the CD45^−^CD34^+^ population was confirmed by fluorescence *in situ* hybridization and genomic PCR analysis (data not shown). The percentage of each subpopulation at each step of sorting was calculated using flow cytometry. In comparison with unsorted placenta, the percentage of CD45^−^CD34^+^ population was increased 16- and 647-fold after CD45^+^ depletion and CD45^+^ depletion and CD34^+^ MACS enrichment, respectively ([Figure S2](#mmc1){ref-type="supplementary-material"}A). The subpopulations based on CD31 levels represented only 0.005%--0.025% of placental populations after CD45^+^ depletion ([Figure S2](#mmc1){ref-type="supplementary-material"}B). These populations were enriched further after CD45^+^ depletion and CD34^+^ magnetic selection, reaching 0.8%--1% of total cells ([Figure S2](#mmc1){ref-type="supplementary-material"}C).

Among the CD45^−^CD34^+^ cells, CD31Lo cells formed 336.9 ± 126.0 colonies per 1 × 10^6^ seeded cells (mean ± SD, [Figures 1](#fig1){ref-type="fig"}G and 1I). This was significantly lower compared with all other CD34^+^ populations. CD31Neg cells resulted in pure mesenchymal colonies ([Figures 1](#fig1){ref-type="fig"}G and 1H), while pure endothelial colonies were derived from CD31Int and CD31Hi populations ([Figures 1](#fig1){ref-type="fig"}G, 1J, and 1K). CD31Neg cells never gave rise to endothelial colonies and, similarly, CD31Int and CD31Hi cells never gave rise to mesenchymal colonies (conclusive results from \>30 placental cell cultures). Further examination identified the HPP-ECFCs to derive almost exclusively from the CD31Int population, and only colonies emanating from the CD31Int population could be further passaged and expanded as expected from ECFCs ([@bib34]). The CD31Hi cells gave rise to mature endothelial clusters with limited proliferative potential. The detailed characterization of the progeny of CD31Neg cells ([@bib21]) has been reported by us recently. In brief, CD31Neg cells once expanded in culture had the morphology, cell surface antigens, and differentiation potential of MSCs ([@bib21]). On the other hand, colonies derived from CD31Int cells had cell surface antigens, gene expression, proliferation, and vasculogenic potential identical to that already described in cord-blood ECFCs ([@bib11], [@bib19]). Overall, it seemed that by using three simple cell surface markers, EPCs and mesenchymal progenitors giving rise to fetal HPP-ECFCs and fetal MSCs, respectively, could be identified.

CD45^−^CD34^+^ CD31Lo Cells Give Rise to Mesenchymal and Endothelial Colonies {#sec2.3}
-----------------------------------------------------------------------------

Of interest, the CD31Lo population contained individual colonies with mixed morphologies of endothelial and mesenchymal cells under EGM2 cell culture conditions. This unique observation led us to suspect the existence of a progenitor with bipotential capacity, and prompted us to examine the differentiation potential of the CD31Lo cells compared with the other three populations in different culture media ([Figure 2](#fig2){ref-type="fig"}A). Among all CD45^−^CD34^+^ populations, only CD31Neg and CD31Lo cells could give rise to colonies in DMEM supplemented with 10% fetal bovine serum (FBS), a standard MSC growth medium ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). None of the CD45^−^CD34^+^ subpopulations could grow in smooth and skeletal muscle medium or displayed hematopoietic capacity ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). Primary skeletal cells, smooth muscle cells ([Figure S2](#mmc1){ref-type="supplementary-material"}B), or placental CD45^+^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}C) were used as positive control for their respective growth media.Figure 2CD45^−^CD34^+^ CD31Lo Population Demonstrated Bipotential Characteristics(A) Placenta-derived cells were cultured in different media for 2--3 weeks, DMEM supplemented with 10% fetal bovine serum (a standard mesenchymal stem cell \[MSC\] growth medium), endothelial growth medium (EGM2, a standard endothelial growth medium), skeletal and smooth muscle cell media, and MethoCult (a standard hematopoietic medium). None of CD45^−^CD34^+^ subpopulations could grow in smooth and skeletal muscle media, or displayed hematopoietic capacity. CD31Neg and CD31Lo cells gave rise to colonies in standard MSC growth medium.(B) *In vitro* characterization of each population cultured in EGM2 using immunofluorescence at passage 2. Upper rows: CD31Neg-derived cells were negative for CD34, UEA-1, CD45, CD31, and CD144, and positive for α-SMA and vimentin. Middle rows: staining of the CD31Lo population resulted in heterogeneous cells expressing CD31, CD144, and UEA-1 in parts of the colony and α-SMA in other parts. Bottom rows: CD31Int-derived cells were negative for CD34, α-SMA, and CD45, but labeled with vimentin, UEA-1, CD31, and CD144. Scale bar, 20 μm.(C) MSC derived from CD31Lo population on passage differentiated into adipocyte and osteoblast lineages after 2 weeks of culture in appropriate differentiation medium. Scale bar, 100 μm.(D) Cell number in each subpopulation after culturing 10,000 fresh isolated and flow-sorted cells in EGM2 after 3 weeks (mean ± SD).

*In vitro* characterization of each population at passage 2 cultured in EGM2 using immunofluorescence staining demonstrated that the CD31Neg-derived colonies were negative for CD34, UEA-1, CD45, CD31, or CD144 and homogeneously positive for vimentin and α-smooth muscle actin (α-SMA; [Figure 2](#fig2){ref-type="fig"}B). In contrast, colonies derived from CD31Int cells were negative for CD34, α-SMA, and CD45, but homogeneously labeled with vimentin, UEA-1, CD31, and CD144 as would be expected from ECFCs ([Figure 2](#fig2){ref-type="fig"}B). The CD31Lo population gave rise to cells homogeneously negative for CD34 and CD45 and positive for vimentin. Most importantly, the colonies derived from the CD31Lo population contained some cells expressing CD31, CD144, UEA-1 while others expressed α-SMA, further supporting the capacity of the CD31Lo cells to give rise to both endothelial and mesenchymal cells within the same colony ([Figure 2](#fig2){ref-type="fig"}B). Upon further culture in EGM2 or in DMEM medium, colonies derived from the CD31Lo population gave rise to pure mesenchymal cells at P3 (data not shown). These cells could differentiate into adipocyte and osteoblast lineages after 2 weeks of culture in appropriate differentiation media ([Figure 2](#fig2){ref-type="fig"}C). Moreover, CD31Lo cells had a population doubling time of 41 ± 6 hr. Additionally, compared with other subpopulations the CD31Lo fraction produced the smallest number of progeny ([Figure 2](#fig2){ref-type="fig"}D).

Bipotential Capacity of CD45^−^CD34^+^ CD31Lo Cells in Limiting Dilution Assay {#sec2.4}
------------------------------------------------------------------------------

### Generating Single Colonies in Limiting Dilution {#sec2.4.1}

To further confirm the bipotency of CD31Lo cells, it was essential to ensure that only single colonies were analyzed and that our observations were not the result of contaminating cells from the CD31Neg or CD31Int populations. Given our reproducible rates of colony formation for each of the CD45^−^CD34^+^ populations, it was expected that only 1 out of every 1,000 cells would give rise to a colony. To ensure that isolated colonies were derived from single cells, we gated and sorted freshly isolated placental CD45^−^CD34^+^ cells based on CD31 level and cultured them in 96-well plates at 10 cells per well, 100-fold below their expected colony-forming frequency. More than 2,500 wells were prepared for each of the four separate CD45^−^CD34^+^ subpopulations. After 2 weeks, colonies derived from each population were evaluated under a microscope ([Figure 3](#fig3){ref-type="fig"}A). As expected, colonies emanating from CD31Neg and CD31Int cells were exclusively mesenchymal and endothelial (cobblestone shape), respectively, in morphology whereas CD31Hi derived cells only formed small clusters that could not be expanded or passaged. Passaging of individual colonies from CD31Neg and CD31Int resulted in similar types of colonies that could be characterized as mesenchymal and endothelial, respectively. This confirmed the existence of pure mesenchymal (positive for CD90, CD105, CD106, and CD146 and negative for CD31, CD45, and CD144) and pure endothelial (positive for CD31, CD34, CD144, and CD146 and negative for CD90, CD45, CD106, and CD117) progenitors in CD31Neg and CD31Int populations, respectively ([Figure S4](#mmc1){ref-type="supplementary-material"}).Figure 3Bipotential Capacity of CD45^−^CD34^+^ CD31Lo Cells in Limiting Dilution Assay(A) CD45^−^CD34^+^ cells were gated and sorted based on CD31 level, and cultured in 96-well plates at 10 cells per well; a total of more than 2,500 wells were prepared for each of the CD45^−^CD34^+^ subpopulations. After 2 weeks, colonies derived from each population were evaluated under the microscope. Scale bar, 100 μm.(B--E) Number and type of colonies harvested from 1 million cells of each CD45^−^CD34^+^ subpopulation after 2--3 weeks. Bipotential cells contained both endothelial and mesenchymal cells (n = 3 independent placentas, data presented as median with interquartile range).(F) Number of high proliferative potential (HPP-) and low proliferative potential (LPP-) endothelial progenitor cells (EPC), and endothelial clusters (EC) isolated from CD31Int and CD31Hi fractions.(G) Schematic suggesting a self-renewal hierarchy among CD31Int and CD31Hi cells *in vivo* and *in vitro*.(H) Individual colonies from CD31Lo population primary culture were stained for CD31, UEA-I, CD144, and fibroblast-specific protein (FSP). Scale bar, 100 μm.(I) Single colonies derived from CD31Lo population were harvested and passaged and resulted in a mixture of endothelial, mesenchymal, and bipotential colonies. Quantitative analysis showed that most colonies are bipotential in passage 1. Scale bar, 100 μm.(J and K) Flow-cytometry analysis on bipotential colonies from CD31Lo cells at passage 1 (J) and passage 3 (K).^∗^p \< 0.05.

Seeding of CD31Lo cells resulted in fewer individual colonies compared with the other two populations (n = 3 placentas, CD31Neg: 2,772 ± 418, CD31Low: 940 ± 163, and CD31Int: 2,453 ± 410 colonies per million seeded cells, mean ± SD; [Figures 3](#fig3){ref-type="fig"}B--3D). Based on the data observed and the large numbers of empty wells, we calculated the probability of monoclonality as previously described for limiting dilution experiments ([@bib14]). For CD31Low seeded cells, the colonies observed had a probability of 0.9996 to be monoclonal. This further ensured that the seeding of 10 cells per well is likely to result in single-cell-derived colonies.

### A Self-Renewal Hierarchy among Endothelial Cells {#sec2.4.2}

We next focused on colonies that could be identified as HPP-EPCs. Colonies were scored as endothelial cluster (EC, \<50 cells), low proliferative potential-EPC (LPP, for 50--2,000 cells), and HPP-EPCs (for \>2,000 cells). Of significant interest, EPCs giving rise to HPP-ECFCs were concentrated in the CD31Int population compared with the CD31Hi population (on average 612 versus 40 HPP-ECFCs per million seeded cells, respectively; [Figures 3](#fig3){ref-type="fig"}D--3F). The CD31Int population also contains larger numbers of LPP-ECFCs (1,222 versus 300 per million seeded cells) but fewer endothelial clusters (232 versus 1,089 per million seeded cells) than the CD31Hi population ([Figure 3](#fig3){ref-type="fig"}F). Altogether, using limiting dilution assay and quantitative analysis, we suggest an endothelial hierarchy between CD31Int and CD31Hi endothelial cells *in vivo* ([Figure 3](#fig3){ref-type="fig"}G). The CD31Int cells represent an *in vivo* population that is therefore enriched with endothelial progenitors that in culture give rise to HPP-ECFCs.

### Mesenchymal and Endothelial Bipotency of the CD31Lo Population {#sec2.4.3}

Further characterization of CD31Lo population cultured at the single-colony level in EGM2 recapitulated the heterogeneity previously observed. All cells were positive for vimentin, whereas for UEA-1, CD31, and CD144 as endothelial markers or FSP1 as a mesenchymal marker, there was heterogeneous and mutually exclusive expression in colonies presumably derived from single cells ([Figure 3](#fig3){ref-type="fig"}H). This clearly supported the capacity of the CD31Lo cells to give rise to both endothelial and mesenchymal cells within the same colony; accordingly these cells were named meso-endothelial bipotent progenitors. Microscopy further suggested derivation of cells of both endothelial and mesenchymal morphology within a single colony (from a single CD45^−^CD34^+^CD31Lo cell) ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B).

To confirm these bipotential features, we next passaged individual colonies presumably isolated from single CD45^−^CD34^+^CD31Lo cells at limited dilution and characterized them further. In this setting, 41% of resulting colonies seemed purely endothelial, 6% were purely mesenchymal, and the remaining 53% were again bipotential ([Figure 3](#fig3){ref-type="fig"}I). Although all cells were CD34 positive, flow-cytometry analysis of secondary bipotential colonies showed heterogeneity in expression of CD31 (13% ± 3% positive), CD144 (17% ± 25% positive), and CD90 (52% ± 32% positive) levels ([Figure 3](#fig3){ref-type="fig"}J); Pure endothelial and mesenchymal colonies obtained from CD31Int and CD31Neg populations expressed CD31 or CD90 in a mutually exclusive way ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). Multicolor flow-cytometric analysis of key markers (CD31, CD34, and CD90) showed that 75% and 24% of cells were CD90^+^ CD34^+^ and CD90^−^CD34^+^. Multicolor staining for CD31, CD34, and CD90 showed that 6% and 7% of cells were CD31^+^CD34^+^ and CD31^+^CD90^+^, respectively ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

However, further passaging resulted in populations of cells negative for endothelial markers (CD31 and CD144, [Figure 3](#fig3){ref-type="fig"}K). This confirmed that colonies could maintain such bipotency at least up to passage 1 in EGM2 medium, allowing gene expression studies at passage-0 cultures ([Figure 4](#fig4){ref-type="fig"}). The phenotype of all populations was investigated up to at least six passages, confirming that only mesenchymal cells could be detected after passage 3 through morphology but also flow cytometry ([Figure 3](#fig3){ref-type="fig"}K) and immunofluorescence (data not shown).Figure 4Meso-Endothelial Bipotent Cells Display Vascular and Mesenchymal Molecular Signature(A) Upon sorting and short-term culture, each population was recovered before passaging and RNA extracted.(B) Unsupervised clustering of all three populations considered together.(C) Expression of endothelial key genes in CD31Neg, Low, and Int populations as validated using qRT-PCR.(D) Expression analysis of pericyte and mesodermal progenitor cell key markers (*ACTA2* and *PDGFRB*, *RUNX2* and *THY1*) was assessed using qRT-PCR.(E) Heatmap showing the comparative analysis between CD31Lo and CD31Int populations (more than 3-fold difference in RNA expression).(F) Comparative expression was validated by qRT-PCR.(G) Differential expression of SOX genes (*SOX9*, *SOX17*, and *SOX18*) was confirmed using qRT-PCR.(H) Higher expression of Notch pathway target genes in CD31Lo and CD31Int populations as confirmed by qRT-PCR.^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.005.

Bipotential Cells Display Vascular and Mesenchymal Molecular Signature {#sec2.5}
----------------------------------------------------------------------

To assess the placental cell population\'s gene expression profile, we performed RNA sequencing on the three placental populations with high colony-forming potential. After sorting and short-term culture to gain a sufficient cell quantity, each population was recovered before passaging and subjected to RNA extraction. Unsupervised clustering distinguished CD31Neg from CD31Lo and CD31Int populations, whereas CD31Lo and Int could not be easily distinguished when all three populations were considered together ([Figures 4](#fig4){ref-type="fig"}A and 4B; [Supplemental Results](#mmc1){ref-type="supplementary-material"}; [Table S5. List of Genes Differentially Expressed between CD31Neg and CD31Int Populations, Related to Figure 4](#mmc2){ref-type="supplementary-material"}, [Table S6. List of Genes Differentially Expressed between CD31Int and CD31Lo Populations, Related to Figure 4](#mmc3){ref-type="supplementary-material"}, [Table S7. List of Genes Differentially Expressed between CD31Lo and CD31Neg Populations, Related to Figure 4](#mmc4){ref-type="supplementary-material"}; SRA accession ID: SRP127770). qRT-PCR confirmed that *PECAM-1* (725×), *CD34* (349×), and *CDH5* (1,390×) genes were upregulated in CD31Int versus CD31Neg ([Figure 4](#fig4){ref-type="fig"}C, p \< 0.01), with the expression of key endothelial genes in CD31Lo cells being lower than in the CD31Int population, *PECAM-1* (0.1×), *CD34* (0.6×), and *CDH5* (0.7×) ([Figure 4](#fig4){ref-type="fig"}C). Higher expression of MSC precursor genes (*PDGFRB*, *ACTA2*, *RUNX2*, and *THY1*) was confirmed using qRT-PCR ([Figure 4](#fig4){ref-type="fig"}D). Only the CD31Neg population could highly express pericyte key markers, chondroitin sulfate proteoglycan 4 (*CSPG4*) and *MUC12*, as confirmed by qRT-PCR ([Table S4](#mmc1){ref-type="supplementary-material"}). Finally, comparative analysis between CD31Lo and CD31Int cells identified differential expression of 14 additional genes (more than 3-fold difference in expression, [Figure 4](#fig4){ref-type="fig"}E and [Table S6](#mmc3){ref-type="supplementary-material"}) as confirmed using qRT-PCR, namely Gremlin 2 (*GREM2*), Signal Peptide, CUB Domain and EGF-Like Domain Containing 3 (*SCUBE3*), and Secreted Phosphoprotein 1 (*SPP1*) ([Figure 4](#fig4){ref-type="fig"}F). Of interest, our cell populations displayed differential expression of SOX genes as confirmed using qRT-PCR; while the CD31Neg population represented higher expression of *SOX9*, the CD31Lo and CD31Int components showed higher expression of *SOX17* and *SOX18* ([Figure 4](#fig4){ref-type="fig"}G). Similarly, NOTCH signaling, previously shown to maintain self-renewal in ECFCs ([@bib22]), was significantly upregulated with its target genes expressed in CD31Lo and CD31Int populations as confirmed by qRT-PCR ([Figure 4](#fig4){ref-type="fig"}H).

Meso-Endothelial Bipotent Progenitors and EPCs Are in Intimal but Subluminal Position within Blood Vessels *In Vivo* {#sec2.6}
--------------------------------------------------------------------------------------------------------------------

Our gene expression findings of widespread CD144 (VE-cadherin, a classical endothelial marker and a product of the *CDH5* gene) expression in CD31Lo populations with mesenchymal potential were surprising and warranted further validation. Primary colonies at passage 0 from CD31Lo cells were immunostained with CD144 antibody and, as demonstrated in [Figure 5](#fig5){ref-type="fig"}A, all cells derived from single colonies were CD144 positive. This differed from immunostaining on established colonies ([Figure 2](#fig2){ref-type="fig"}B) where cells harboring endothelial markers were sparsely distributed.Figure 5Meso-Endothelial Bipotent Progenitors and Endothelial Progenitor Cells Were Further Characterized Based on Level of CD144 Expression *In Vivo*(A) CD31Lo population highly express CD144 marker at primary culture. Scale bars, 200 μm (low magnification) and 50 μm (high magnification).(B) The CD45^−^CD34^+^ populations were examined for CD144 expression *in vivo*. CD31Lo and CD31Int cells were divided in two categories based on CD144 expression. Sorted cells were cultured in coated plates with EGM2.(C) The CD31NegCD144Neg progenitors gave rise to mesenchymal cells. The CD31Lo bipotential progenitors were within the CD144^+^ fraction. Highly proliferative EPCs were isolated from the CD31IntCD144^+^ population and CD31HiCD144^+^ cells formed endothelial clusters with no proliferation potential in subsequent passages. Scale bar, 100 μm.(D--G) The use of CD144 allowed further enrichment in EPCs and bipotent progenitors.(H) Upon *in vitro* culture and in passage 2, cells were stained with CD144 antibody and the CD31Neg population gave rise to CD144^−^ cells, CD31Lo/CD144^+^ population gave rise to a mixture of CD144^+^ and CD144^−^ cells, and CD31Int/CD144^+^ ended up with CD144^+^ cells. Scale bar, 50 μm.(I and J) Representative images of placental sections stained with CD34 and CD144 antibodies. As expected, all positive cells reside in an intimal position within vascular structures. Scale bar, 100 μm.(K) Placental arteries were firstly washed with PBS and then perfused with FITC-conjugated *Ulex europaeus* agglutinin I (UEA-I) and a single-cell suspension prepared. The single-cell suspension was stained with antibodies and sorted. On sorting, almost all CD31Neg cells were UEA-I negative, and CD31Hi cells were entirely UEA-I positive. However, CD31Lo and CD31Int populations had UEA-I-positive and -negative fractions.(L) Placental sections stained with UEA-I antibody; all (UEA-I)^+^ cells reside in intimal position within vascular structures. Scale bar, 50 μm.(M) Upon *in vitro* culture and in passage 2, the CD31Neg population gave rise to (UEA-I)^−^ cells; however, the CD31Lo/(UEA-I)^−^ population gave rise to both (UEA-I)^+^ and (UEA-I)^−^ cells and CD31Int/(UEA-I)^−^ ended up with (UEA-I)^+^ cells. Scale bar, 50 μm.(N) Placental sections stained with CD34 and osteopontin (OPN) antibodies. Some cells are CD34^+^ OPN^+^ (white arrows). Scale bars, 100 μm (left) and 10 μm (right).(O) Placental sections stained with CD144 and osteopontin (OPN) antibodies. Arrows indicate CD144^+^ OPN^+^ cells. Some cells are subluminal (red arrows) and some are in luminal (white arrows) position. Scale bars, 100 μm (left) and 10 μm (right).

To validate this finding, we studied the CD45^−^CD34^+^ populations *in vivo* to analyze CD144 expression. Among CD45^−^CD34^+^ cells obtained from placental cell suspensions, CD31Neg cells were CD144 negative based on FMO analysis ([Figure 5](#fig5){ref-type="fig"}B). In contrast, all CD31Hi cells were CD144 positive. However, CD31Int cells and mostly CD31Lo could be divided in two distinct categories based on CD144 expression. Therefore, six individual CD45^−^CD34^+^ populations were sorted based on CD31 and CD144 expression levels after gating on CD45^−^CD34^+^ population ([Figures 5](#fig5){ref-type="fig"}B and 5C) and cultured in EGM2. This demonstrated that the mesenchymal progenitors among the CD31Neg population were indeed CD144Neg ([Figures 5](#fig5){ref-type="fig"}C and 5D) and that the mature ECs obtained from the CD31Hi population were CD144^+^ as expected ([Figures 5](#fig5){ref-type="fig"}C and 5G). Of significant interest, EPCs giving rise to HPP-ECFCs were concentrated in the CD31IntCD144^+^ population, and no proliferative endothelial colony could be recovered from the CD31Int/CD144-population ([Figures 5](#fig5){ref-type="fig"}C and 5F).

Importantly, the CD31Lo meso-endothelial progenitors were also within the CD144^+^ fraction and no colonies could be obtained from the CD31LoCD144^−^ cells ([Figures 5](#fig5){ref-type="fig"}C and 5E). This clearly validated our gene expression observations in the CD31Lo population. On a practical note, the use of CD144 allowed a further 4.8-fold enrichment in EPCs as identified by CD31Int expression and a 9.4-fold enrichment in meso-endothelial progenitors, since 3,186 colonies per million seeded cells could be obtained in CD45^−^CD34^+^CD31LoCD144^+^ (compared with 336 colonies \[[Figure 1](#fig1){ref-type="fig"}I\] if using CD45^−^CD34^+^CD31Lo alone) ([Figure 5](#fig5){ref-type="fig"}E).

Upon culture, the CD31Lo/CD144^+^ population gave rise to a mixture of CD144^+^ and CD144^−^ cells in established colonies and displayed the two mesenchymal and endothelial morphologies ([Figure 5](#fig5){ref-type="fig"}H). However, after three passages CD144 expression was lost in parallel with the progression of cultures toward a mesenchymal phenotype. This suggested that *in vivo*, both EPCs and bipotent progenitors are CD144 positive. We therefore stained placental sections for CD144 and observed, as expected, that all positive cells reside in intimal positions within vascular structures suggesting that *in vivo*, unlike mesenchymal progenitors, EPCs and bipotent progenitors are in the intima of blood vessels ([Figures 5](#fig5){ref-type="fig"}I and 5J).

We next assessed whether the CD45^−^CD34^+^ populations were in contact with the circulation. Placental fetal arteries were perfused by fluorescein isothiocyanate (FITC)-conjugated *Ulex europaeus* agglutinin I (UEA-I), a lectin that binds specifically to endothelial cells ([Figure S6](#mmc1){ref-type="supplementary-material"}). This would only stain populations of endothelial cells in contact with the lumen of perfused arteries harboring the appropriate glycoprotein and glycolipid chains recognized by the lectin. After perfusion, the placental arteries and the immediate surrounding chorionic tissue were dissected and analyzed by flow cytometry ([Figures S6](#mmc1){ref-type="supplementary-material"} and [5](#fig5){ref-type="fig"}K). After gating on the CD45^−^CD34^+^ population, CD31Hi cells were expectedly and entirely UEA-I positive, validating successful labeling of all mature endothelial cells ([Figure 5](#fig5){ref-type="fig"}K). On the other hand, CD31Neg cells enriched for mesenchymal progenitors were entirely negative, consistent with the specificity of the lectin labeling. CD31Int cells harboring the EPCs as well as the CD31Lo cells harboring bipotential progenitors had positive and negative fractions ([Figure 5](#fig5){ref-type="fig"}K).

We next sorted and cultured each of the six populations described above. Almost all cells in CD31Neg/UEA-INeg cells gave rise to mesenchymal colonies. Even if UEA-I-positive and -negative cells were observed in the CD31Lo population, only the UEA-I-negative cells gave rise to colonies that had the bipotential morphology ([Figure 5](#fig5){ref-type="fig"}K). To our surprise and similarly, only CD31Int/UEA-INeg cells could give rise to HPP-ECFCs upon culture ([Figure 5](#fig5){ref-type="fig"}K). None of the UEA-I-positive fractions including the CD31Hi population could form proliferative colonies and were restricted to non-proliferating ECs upon culture. In addition, immunofluorescence of placental sections with UEA-I showed that only cells in the luminal position had positive staining ([Figure 5](#fig5){ref-type="fig"}L).

Of interest, ECFCs derived from the CD31Int/UEA-INeg population could be homogeneously labeled with UEA-I after culturing in EGM2 ([Figure 5](#fig5){ref-type="fig"}M), indicating that endogenous EPCs *in vivo* were UEA-1 negative, either because they were not in contact with the circulation or because at a progenitor stage they did not have the lectin binding capacity acquired further in culture. We then stained placental sections using CD144 and osteopontin co-staining (SPP1 or OPN) as identified previously in RNA sequencing ([Figure 4](#fig4){ref-type="fig"}). CD34^+^OPN^+^ or CD144^+^OPN^+^ cells were in the intima of blood vessels. However, they could be found in either luminal (white arrow) or subluminal (red arrow) positions ([Figures 5](#fig5){ref-type="fig"}N and 5O). Overall our experiments indicate that EPCs and bipotent progenitors are derived from the vasculature, and express CD144 do not yet reside in contact with the circulation.

Inhibition of NOTCH Signaling Inhibits Colony Establishment from Meso-Endothelial Progenitors and EPCs {#sec2.7}
------------------------------------------------------------------------------------------------------

Gene expression analysis suggested that NOTCH signaling may be involved in lineage determination of CD45^−^CD34^+^ cells. We recently reported the important role of NOTCH signaling in self-renewal of HPP-ECFCs *in vitro* ([@bib22], [@bib29]). To evaluate the role of NOTCH signaling in the lineage determination of placental populations *in vivo*, we cultured sorted cells in the presence of the γ-secretase inhibitor DAPT in EGM2 ([Figure 6](#fig6){ref-type="fig"}A). As expected, colony formation and cell growth for the CD31Neg population was unaffected compared with the control group (DMSO treated) ([Figure 6](#fig6){ref-type="fig"}B). Of interest, neither the CD31Lo nor CD31Int population was able to grow in the presence of DAPT despite the establishment of colonies. Compared with controls, these colonies could not be passaged. This provided the indication that NOTCH pathway is activated as supported by RNA sequencing data. Notch plays an essential role in bipotential and EPC populations *in vivo*, as the growth of colonies from CD31Lo, CD31Int populations was severely inhibited ([Figure 6](#fig6){ref-type="fig"}B, results from three independent placentas). This was further confirmed through staining of HEY1 and NOTCH1 that displayed an intranuclear localization in EPC and meso-endothelial colonies ([Figures 6](#fig6){ref-type="fig"}C and 6D). Finally, pharmacological inhibition of the NOTCH pathway had no effect on the CD31Hi population compared with control. Altogether, inhibition of NOTCH signaling using DAPT counteracts the bipotential and EPC populations, yet had no effect of mesenchymal progenitors and mature endothelial cells.Figure 6Inhibition of NOTCH Signaling Counteracts Meso-Endothelial Bipotent and Endothelial Progenitor Cell Growth(A) Placental cells were sorted and cultured in the presence of the γ-secretase inhibitor (DAPT, 50 μM) or DMSO (control group) in endothelial growth medium (EGM2).(B) Neither CD31Lo nor CD31Int population grew in the presence of DAPT, while culture in DMSO resulted in meso-endothelial bipotent cells (CD31Lo) and EPC (CD31Int) colonies in passage 1.(C and D) Placental cells were sorted and cultured in the culture slides for 2 weeks and the primary colonies were stained for CD144 and HEY 1 (C) or CD144 and NOTCH1 (D) antibodies.Scale bars, 100 μm (A and B) and 20 μm (C and D).

Differentiation of Meso-Endothelial Bipotent Cells to Mesenchymal Lineage Is Not Mediated by Transforming Growth Factor β1 {#sec2.8}
--------------------------------------------------------------------------------------------------------------------------

Compared with CD31Int cells, bipotential CD31Lo cells expressed genes suggestive of activated transforming growth factor β (TGFβ)/bone morphogenetic protein pathway (SCUBE3 and Gremlin). We therefore hypothesized that CD31Lo cells can give rise to mesenchymal lineages through TGFβ1-driven endothelial-to-mesenchymal transdifferentiation (EndMT). To address this hypothesis, we cultured CD45^−^CD34^+^ subpopulations with TGFβ inhibitor or DMSO after cell sorting and investigated their progeny ([Figure 7](#fig7){ref-type="fig"}A). The characteristics of CD45^−^CD34^+^ subpopulations were not affected in the DMSO-treated group ([Figure 7](#fig7){ref-type="fig"}B). Addition of SB431542, an inhibitor of the TGFβ1 receptor activity ([@bib12]), did not inhibit the growth of CD31Neg, Low, or Int populations ([Figure 7](#fig7){ref-type="fig"}C). Culture in the presence of SB431542 resulted in formation of endothelial and mesenchymal cells in the CD31Lo population as expected. Additional formation of ECFCs in the CD31Int population was not affected compared with the control group (DMSO treated) in primary culture. Of interest, TGFβ pathway inhibition increased the level of colony-formation capacity in the CD31Lo population compared with the control group (8,577 ± 996 compared with 3,395 ± 1,950 in 10^6^ seeded cells, respectively; not significant, results from three independent placentas, [Figure 7](#fig7){ref-type="fig"}D). Addition of SB431542 to the CD31Lo population had no effect on expression of endothelial genes (*PECAM-1*, *CD34*, and *CD144*) compared with the CD31Int population ([Figure 7](#fig7){ref-type="fig"}E). Altogether, these findings suggest that the formation of mesenchymal cells from the bipotential population is not mediated through a classical EndMT pathway. This was further confirmed through staining of placental sections for CD31 and SNAIL/SLUG antibodies. Immunohistochemistry showed no expression of SNAIL/SLUG by CD31^+^ cells ([Figure 7](#fig7){ref-type="fig"}F). Immunostaining of primary colonies demonstrated that only the CD31Neg subpopulation expressed SNAIL/SLUG ([Figure 7](#fig7){ref-type="fig"}G). Neither EPC nor meso-endothelial colonies stained for SNAIL/SLUG ([Figure 7](#fig7){ref-type="fig"}G).Figure 7Differentiation of Meso-Endothelial Bipotent Cells to Mesenchymal Lineage Is Not Mediated by the TGFβ Pathway(A) On sorting, CD45^−^CD34^+^ subpopulations were cultured with SB431542 (TGFβ inhibitor, 10 μM) or DMSO (control group).(B) Culture in the presence of SB431542 resulted in bipotential (CD31Lo) and EPC (CD31Int) colonies in passage 1.(C) Addition of SB431542 did not inhibit the growth of CD31Neg, Low or Int populations in passage 1.(D) TGFβ pathway inhibition increased the level of colony-formation capacity in CD31Lo population compared with the control group (ns, not significant; result from three independent placentas).(E) qRT-PCR analysis confirmed that expression of endothelial genes (*PECAM-1*, *CD34*, and *CD144*) was not affected in the presence of SB431542 compared with the CD31Int population.(F) Placental sections were stained for CD31 and SNAIL SLUG markers.(G) Placental cells were sorted and cultured on the culture slides for 2 weeks, then primary colonies were stained for CD31 and SNAIL SLUG antibodies. Scale bars, 100 μm (B, C, and F) and 20 μm (G).

Discussion {#sec3}
==========

Until recently it was postulated that neo-vessel formation in adults is only mediated by angiogenesis. This view has been challenged recently by endothelial precursors being isolated in postnatal life ([@bib1], [@bib25]), although the ontogeny of EPCs is not fully understood. The mesodermal origin of the endothelium allows the hypothesis of the existence of a common bipotent progenitor postdevelopmentally, capable of giving rise to both vasculature and mesenchymal progeny. Here, using a cell surface marker based sorting strategy and subsequent colony-forming assays in limiting dilution assays, we have identified *in vivo* a common precursor of mesenchymal and endothelial cells from human term placenta. These bipotential precursors showed differentiation potential to both endothelial and mesenchymal colonies upon culture. Of equal importance, we also identified *in vivo* progenitors that give rise to ECFC colonies. These findings allowed us to decipher the hierarchy between bipotential endothelial progenitors and mature endothelial cells *in vivo*.

Many studies have attempted to identify *in vivo* populations with mesodermal progenitor activity using markers such as c-kit, CD133, and CD45, but most of these markers are also expressed in hematopoietic cells ([@bib5], [@bib10]). We therefore designed a sorting strategy to deplete the CD45^+^ population. Furthermore, since CD34 has been broadly used as an endothelial progenitor ([@bib5], [@bib23]) and has provided our previous observations in situations of feto-maternal chimerism ([@bib16], [@bib17]), we used the CD45^−^CD34^+^ population as an enriched source of progenitors with endothelial potential. However, culturing the CD34^+^ population resulted in contaminating mesenchymal cells, as previously reported ([@bib32]). In addition, fetal mesenchymal cells have been reported recently to express CD34^+^ (reviewed in [@bib30]), highlighting the need for additional markers such as CD31, CD144, or UEA-I. Precise cell surface markers for mesenchymal progenitors (CD45^−^CD34^+^CD31^−^CD144^−^UEA-I^−^), EPCs (CD45^−^CD34^+^CD31IntCD144^+^UEA-I^−^), and meso-endothelial bipotent progenitors (CD45^−^CD34^+^CD31LoCD144^+^UEA-I^−^) were established, while use of CD90, CD105, CD106, and CD146 documented the expected phenotype of endothelial versus mesenchymal potential. Meso-endothelial progenitors described here did not show propensity for expansion in skeletal muscle growth medium, suggesting a significant phenotype difference from previously described cells ([@bib8], [@bib28], [@bib31]). However, this could be related to culture conditions whereby bipotential cells isolated from muscle may be more likely to adopt a muscle phenotype. An important finding was the lack of staining of meso-endothelial progenitors and EPCs by UEA-I injected intravascularly. Although we cannot rule out the complete absence of the residues required for this lectin attachment at their stage of differentiation, the most plausible explanation is that these progenitors, despite expressing CD144 (VE-cadherin), are not in contact with the circulation, suggesting they are subintimal. However, further studies are needed to confirm this finding. In contrast, mesenchymal progenitors did not seem to be specifically associated with blood vessels. Expression of CD34 has, however, been associated with a pericyte phenotype rather than a neural crest-derived phenotype ([@bib32]) ([Supplemental Discussion](#mmc1){ref-type="supplementary-material"}).

Freshly isolated endothelial cells had significant heterogeneity in their ability to generate colonies. As reported previously ([@bib11]), this could suggest a hierarchy in self-renewal among endothelial cells within the CD45^−^CD34^+^ cells. Accordingly, the CD31Int population that could form HPP-ECFC may be considered as the progenitor of CD31Hi cells *in vivo* that only formed non-proliferating endothelial clusters. This strongly suggests a hierarchy among endothelial cells *in vivo*, recapitulating similar findings in mice as reported recently by us ([@bib20]).

In conclusion, our study identifies and defines *in vivo* populations of fetal progenitors that can give rise to endothelial, mesenchymal, or both types of colonies ([Figure S7](#mmc1){ref-type="supplementary-material"}A). The characterization of a bipotent mesenchymal and endothelial progenitor further confirms their importance from not only a developmental biology but also from a regenerative medicine point of view. Of interest, these meso-endothelial bipotent progenitors were closely associated with the vasculature ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Current discovered and characterized cell phenotypes might show great potential to be further explored in regenerative medicine applications for vessel formation.

Experimental Procedures {#sec4}
=======================

FACS Analysis {#sec4.1}
-------------

Antibodies used for fluorescence-activated cell sorting (FACS) are detailed in [Table S1](#mmc1){ref-type="supplementary-material"}. Placental tissues were cut and single-cell suspensions prepared as reported previously ([@bib19], [@bib21]). Single-cell suspensions upon digestion were denoted "unsorted population" and cultured in DMEM (Gibco, USA) supplemented with 10% FBS (Gibco), or in the endothelial cell growth medium (EGM2; Lonza, USA). For removal of hematopoietic populations, unsorted cells were resuspended in ice-cold MACS buffer (PBS \[Lonza\]/0.5% BSA \[Sigma\]/2.5 mM EDTA disodium salt \[Merck, Darmstadt, Germany\]) and incubated in Dynabeads CD45 (Invitrogen, USA) for 20 min and the CD45^+^ cells depleted by using a magnet (DynaMag-15; Invitrogen). For enrichment of endothelial cells, CD45 cells were incubated in CD34 MicroBeads (Miltenyi Biotech, Germany) for 20 min on ice and then loaded onto a MACS column (25 LS Columns) placed in the magnetic field of an MACS Separator. The final CD45^−^CD34^+^ cells were stained using 7-amino-actinomycin D (7-AAD, dilution 1:40) for exclusion of dead cells and also stained with CD34 (dilution 1:25), CD45 (dilution 1:25), and CD31 (dilution 1:30) antibodies ([Table S1](#mmc1){ref-type="supplementary-material"}) for 20 min at 4°C. Cells were sorted using the FACSAria 11u (BD Biosciences, MA) machine. Upon analysis using a pulse geometry gate, cell doublets were eliminated and the CD34^+^ Hi CD45^−^ population was gated and sorted into four populations according to the level of CD31 expression. For culture experiments, populations of interest were sorted directly into 100% FBS and then cultured individually in collagen-coated 48-well plates with EGM-2. On day 14 of culture, colonies were counted, analyzed, and passaged.

Perfusion of Placental Vessels with FITC-Conjugated UEA-I {#sec4.2}
---------------------------------------------------------

Upon delivery a portion of the placenta was cut and separated under aseptic conditions. Fetal chorionic and amniotic membranes were removed and placental vessels perfused and washed off three times with Ca^2+^- and Mg^2+^-free PBS (Gibco). Cleaned vessels were further infused with 10 mL of UEA-I (1:125 dilution) and incubated at room temperature for 10 min. Finally the arteries were cut, enzymatically digested, and sorted as indicated.

Statistical Analysis {#sec4.3}
--------------------

Analyses were performed using GraphPad Prism v6.04 software. Descriptive statistics were provided for mean ± SD. Groups were compared by Student's t tests and one- or two-way ANOVA for parametric variables. A Mann-Whitney U test was used to compare non-parametric variables. p Values of \<0.05 were considered statistically significant. Here, data represented by histograms and dot plots are the conclusion of at least three independent samples in triplicate unless specified otherwise.
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